Soutien à la recherche

Dans le cadre de sa politique scientifique en recherche respiratoire,

L’association le Nouveau Souffle se propose de financer l’année 2020, des projets de recherche pour un budget global de 100 000 Mille euros.

Travaux post-doctoraux de recherche médicale

L’association « le nouveau souffle » lance un appel d'offres pour des travaux post-doctoraux de recherche médicale sous forme d'une bourse de thèse et / ou mobilité, en relation avec la pneumologie avec un montant maximum de 20 000 euros par projet.

Contactez nous

Vous avez une idée qui vous semble prometteuse ?

Travaillons ensemble pour faire avancer la recherche dans le domaine de la santé respiratoire.

Previous Next Play Pause
mardi, 14 mai 2019 20:00

The ALLOZITHRO Randomized Clinical Trial

Écrit par
Évaluer cet élément
(0 Votes)

Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic Hematopoietic Stem Cell Transplant

 

Importance

Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post–lung transplant bronchiolitis obliterans syndrome.

 

 

Objective : To evaluate if the early administration of azithromycin can improve airflow decline–free survival after allogeneic HSCT.

Design, Setting, and Participants

The ALLOZITHRO parallel-group trial conducted in 19 French academic transplant centers and involving participants who were at least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had available pretransplant pulmonary function test results. Enrollment was from February 2014 to August 2015 with follow-up through April 26, 2017.

 

Interventions : Patients were randomly assigned to receive 3 times a week either 250 mg of azithromycin (n = 243) or placebo (n = 237) for 2 years, starting at the time of the conditioning regimen.

Main Outcomes and Measures : The primary efficacy end point was airflow decline–free survival at 2 years after randomization. Main secondary end points were overall survival and bronchiolitis obliterans syndrome at 2 years.

 

Results

Thirteen months after enrollment, the independent data and safety monitoring board detected an unanticipated imbalance across blinded groups in the number of hematological relapses, and the treatment was stopped December 26, 2016. Among 480 randomized participants, 465 (97%) were included in the modified intention-to-treat analysis (mean age, 52 [SD, 14] years; 75 women [35%]). At the time of data cutoff, 104 patients (22%; 54 azithromycin vs 50 placebo) had experienced an airflow decline; 138 patients (30%) died (78 azithromycin vs 60 placebo). Two-year airflow decline–free survival was 32.8% (95% CI, 25.9%-41.7%) with azithromycin and 41.3% (95% CI, 34.1%-50.1%) with placebo (unadjusted hazard ratio [HR], 1.3; 95% CI, 1.02-1.70; P = .03). Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the azithromycin group and 7 (3%) in the placebo group (P = .08). The azithromycin group had increased mortality, with a 2-year survival of 56.6% (95% CI, 50.2%-63.7%) vs 70.1% (95% CI, 64.2%-76.5%) in the placebo group (unadjusted HR, 1.5; 95% CI, 1.1-2.0; P = .02). In a post hoc analysis, the 2-year cumulative incidence of hematological relapse was 33.5% (95% CI, 27.3%-39.7%) with azithromycin vs 22.3% (95% CI, 16.4%-28.2%) with placebo (unadjusted cause-specific HR, 1.7; 95% CI, 1.2-2.4; P = .002).

 

Conclusions and Relevance

Among patients undergoing allogeneic HSCT for hematological malignancy, early administration of azithromycin resulted in worse airflow decline–free survival than did placebo; these findings are limited by early trial termination. The potential for harm related to relapse requires further investigation.

Auteurs :

Anne Bergeron, MD, PhD, Sylvie Chevret, MD, PhD, Angela Granata, MD, Patrice Chevallier, MD, PhD, Laure Vincent, MD, Anne Huynh, MD, Reza Tabrizi, MD, Hélène Labussiere-Wallet, MD, Marc Bernard, MD, Sylvain Chantepie, MD, Jacques-Olivier Bay, MD, PhD, Anne Thiebaut-Bertrand, MD, Sylvain Thepot, MD, PhD, Nathalie Contentin, MD, Luc-Matthieu Fornecker, MD, PhD, Natacha Maillard, MD, Karine Risso, MD, Ana Berceanu, MD, PhD, Didier Blaise, MD, PhD, Regis Peffault de La Tour, MD, PhD, Jason W. Chien, MD, MSc, Valérie Coiteux, MD, and Gérard Socié, MD, PhD, for the ALLOZITHRO Study Investigators

Logo of jamasd JAMA Network View Article
. 2017 Aug 8; 318(6): 557–566.
Published online 2017 Aug 8. doi: 10.1001/jama.2017.9938
Lu 34 fois Dernière modification le mercredi, 15 mai 2019 20:02

Éléments similaires (par tag)

Connectez-vous pour commenter